superior protection get your cattle off to a stronger ......respiratory disease remains the most...
TRANSCRIPT
sUpEriOr prOTECTiON riGHT FrOM THE sTArT.
1 Brodersen BA, Bovine respiratory syncytial virus. Vet Clin Food Anim 2010;26:323-333.2 NAHMS Beef Cow/Calf Health & Productivity Audit; Part III: Beef Cow/Calf Health Management, January 2008. Available at: http://www.aphis.usda. Accessed July 2010.3 Edwards AJ. Respiratory diseases of feedlot cattle in the USA. Bovine Practitioner 1996;30:5-7.4 Galyean ML, Perino LJ, Duff CG. Interaction of cattle health/immunity and nutrition. J Anim Sci 1999;77:1120-1134.5 Loneragan DH, Dargatz DA, Morley PS, et al. Trends in mortality rates among cattle in U.S. feedlots. J Amer Vet Med Assoc 2001;219:1122-1127.6 NAHMS Dairy 2007 Part I: Reference of Dairy Cattle Health and Management Practices in the United States, October 2007. Available at: http://www.aphis.usda. Accessed July 2010.7 Steven T, Grubbs ST, Kania SA, Potgieter LND. Prevalence of ovine and bovine respiratory syncytial virus infections in cattle determined with a synthetic peptide-based immunoassay. J Vet Diagn Invest 2001;13:128–132. 8 Valarcher JF, Geraldine Taylor G. Bovine respiratory syncytial virus infection Vet Res 2007;38:153-180. 9 Ellis JA. Bovine parainfluenza-3 virus, Vet Clin Food Anim, 2010 (In press).10 Data on file, Study Report No. 3131R-60-08-557, Pfizer Inc.11 Data on file, Study Report No. 3131R-60-09-669, Pfizer Inc.12 Data on file, Study Report No. 3131R-60-08-580, Pfizer Inc. 13 Data on file, Study Report No. 3131R-60-09-720, Pfizer Inc. 14 Data on file, Study Report No. 3131R-60-08-568, Pfizer Inc.15 Data on file, Study Report No. 3437R-60-09-716, Pfizer Inc.16 Data on file, Study Report No. 3131R-60-09-671, Pfizer Inc.17 Data on file, Study Report No. 3131W-60-09-672, Pfizer Inc.
All brands are the property of Pfizer Inc., its affiliates and/or its licensors. ©2010 Pfizer Inc. All rights reserved. INF10006
Get your cattle off to a stronger, healthier start with iNFOrCE 3. To learn more, contact
your pfizer Animal Health representative, call 800-733-5500 or visit www.pfizerah.com.
Team up with your veterinarian to develop a complete vaccination protocol, starting with iNFOrCE™ 3.• INFORCE 3 helps give cattle a stronger start for greater productivity• Early protection can help reduce susceptibility to secondary bacterial infections• For dairy herds, use INFORCE 3 in baby calves, on arrival, at weaning,
before moving to group pens, or with cows and heifers prefreshening• INFORCE 3 is perfect for use in calves in beef herds at branding, preconditioning,
weaning, pre-shipment or on arrival in stocker or feedlots
A strong foundation for a complete vaccination protocol.
iNFOrCE 3 is available in four convenient dose sizes.
safe for use in all types, ages and classes of cattle.
The safety of iNFOrCE™ 3 was demonstrated in three separate studies.
1. Field safety study15:
The safety of INFORCE 3 was evaluated in a cattle safety study, which was one of the largest
ever conducted by Pfizer Animal Health. INFORCE 3 was administered intranasally to:
• 0- to 8-day-old calves • Pregnant cows in all three trimesters • Weaned calves • Total of 1,873 animals • High-stress stocker cattle • Three geographic locations
rEsULTs — iNFOrCE 3: sAFE iN ALL TYpEs, AGEs AND CLAssEs OF CATTLE
2. intensive safety study in young calves16:
INFORCE 3 and a commercial 5-way intranasal vaccine were both administered intranasally:
• A 10X concentrated dose to 3- to 10-day-old colostrum-deprived calves. • A dose of a commercial vaccine was administered parenterally to all animals 14 days
post-intranasal dose.
rEsULTs — iNFOrCE 3: sAFE iN YOUNG CALvEs
3. High-risk stocker study17:
INFORCE 3 and a commercial 5-way intranasal vaccine were both administered intranasally to:
• High-risk stocker calves on arrival at a feedlot
• A dose of a commercial vaccine was administered parenterally to all calves 14 days
post-intranasal dose
rEsULTs — iNFOrCE 3: sAFE iN HiGH-risK sTOCKEr CATTLE
The costs of respiratory disease are astounding. Brsv can be prevented. A strong defense against iBr and pi3 viruses.
• Prevalence of 41% to 70% in U.S.7
• BRSV infection is
associated with high
morbidity (60% to 80%)8
• Fatality rates may
be as high as 20%8
$1BANNUAL COsT
#1BEEF
#2DAirY
It has been estimated that BRD costs the cattle industry $1 billion
annually from death, reduced feed efficiency and treatment costs.1
iNFOrCE™ 3 is the first and only respiratory vaccine to be granted the “prevention of disease” indication, the highest label claim available for Brsv protection.
Respiratory disease remains the most economically devastating
condition in the beef industry2
• Approximately 75% of feedlot illnesses3,4,5
• 50% of feedlot deaths3,4,5
The second-most significant disease in dairy operations.6
• 22% of unweaned heifer deaths6 • 46% of weaned heifer deaths6
Brsv iBr
iNFOrCE 3 = NO DEATHs
All INFORCE 3 vaccinates survived
severe BRSV challenges, while almost
all unvaccinated controls died.10,11
20%
40%
60%
80%
100%
3- to 9-day-old calves*
(P 0.0001)
6- to 8-week-old calves*
(P 0.0001)
0%
–< –<
% M
orta
lity
100%90%
0% 0%
INFORCE 3 Control
iNFOrCE 3 = LEss LUNG DAMAGE
Fewer lung lesions due to BRSV
infections mean INFORCE 3 vaccinates
should be expected to require reduced
labor and treatment costs, and
improved productivity.9,10
20%
40%
60%
3- to 9-day-old calves*
(P=0.0006)
6- to 8-week-old calves*
(P<0.0001)
0%
% L
ung
Dam
age
57.6%
13.5%
43.8%
5.8%
INFORCE 3 Control
INFORCE 3 Control
iNFOrCE 3 = LEss iBr DisEAsE
Fewer sick calves mean less treatment
cost, reduced labor requirements
and decreased chance of secondary
bacterial infection.12,13
20%
40%
60%
80%
100%
3- to 9-day-old calves*
(P 0.0001)
6- to 8-week-old calves*
(P 0.0001)
0%
< <
% M
orbid
ity
100%100%
5.6% 5%
iNFOrCE 3 = LEss pi3 virUs sHEDDiNG
Compared with unvaccinated controls,
INFORCE 3 vaccinates shed 99.9% less
PI3 virus after challenge.14
99.9%LEss virUs sHED
Developed specifically for intranasal use.
• Helps stimulate local immunity• Triggers a rapid innate immune response• Helps provide protection where viruses attack first• Helps prime the immune system for a strong
memory response to subsequent disease challenges
pi3
• Immunosuppressive• May predispose cattle
to bacterial pneumonia9
• Easily spread• Causes severe upper
respiratory infections• Possible latent
infection
The costs of respiratory disease are astounding. Brsv can be prevented. A strong defense against iBr and pi3 viruses.
• Prevalence of 41% to 70% in U.S.7
• BRSV infection is
associated with high
morbidity (60% to 80%)8
• Fatality rates may
be as high as 20%8
$1BANNUAL COsT
#1BEEF
#2DAirY
It has been estimated that BRD costs the cattle industry $1 billion
annually from death, reduced feed efficiency and treatment costs.1
iNFOrCE™ 3 is the first and only respiratory vaccine to be granted the “prevention of disease” indication, the highest label claim available for Brsv protection.
Respiratory disease remains the most economically devastating
condition in the beef industry2
• Approximately 75% of feedlot illnesses3,4,5
• 50% of feedlot deaths3,4,5
The second-most significant disease in dairy operations.6
• 22% of unweaned heifer deaths6 • 46% of weaned heifer deaths6
Brsv iBr
iNFOrCE 3 = NO DEATHs
All INFORCE 3 vaccinates survived
severe BRSV challenges, while almost
all unvaccinated controls died.10,11
20%
40%
60%
80%
100%
3- to 9-day-old calves*
(P 0.0001)
6- to 8-week-old calves*
(P 0.0001)
0%
–< –<
% M
orta
lity
100%90%
0% 0%
INFORCE 3 Control
iNFOrCE 3 = LEss LUNG DAMAGE
Fewer lung lesions due to BRSV
infections mean INFORCE 3 vaccinates
should be expected to require reduced
labor and treatment costs, and
improved productivity.9,10
20%
40%
60%
3- to 9-day-old calves*
(P=0.0006)
6- to 8-week-old calves*
(P<0.0001)
0%
% L
ung
Dam
age
57.6%
13.5%
43.8%
5.8%
INFORCE 3 Control
INFORCE 3 Control
iNFOrCE 3 = LEss iBr DisEAsE
Fewer sick calves mean less treatment
cost, reduced labor requirements
and decreased chance of secondary
bacterial infection.12,13
20%
40%
60%
80%
100%
3- to 9-day-old calves*
(P 0.0001)
6- to 8-week-old calves*
(P 0.0001)
0%
< <
% M
orbid
ity
100%100%
5.6% 5%
iNFOrCE 3 = LEss pi3 virUs sHEDDiNG
Compared with unvaccinated controls,
INFORCE 3 vaccinates shed 99.9% less
PI3 virus after challenge.14
99.9%LEss virUs sHED
Developed specifically for intranasal use.
• Helps stimulate local immunity• Triggers a rapid innate immune response• Helps provide protection where viruses attack first• Helps prime the immune system for a strong
memory response to subsequent disease challenges
pi3
• Immunosuppressive• May predispose cattle
to bacterial pneumonia9
• Easily spread• Causes severe upper
respiratory infections• Possible latent
infection
The costs of respiratory disease are astounding. Brsv can be prevented. A strong defense against iBr and pi3 viruses.
• Prevalence of 41% to 70% in U.S.7
• BRSV infection is
associated with high
morbidity (60% to 80%)8
• Fatality rates may
be as high as 20%8
$1BANNUAL COsT
#1BEEF
#2DAirY
It has been estimated that BRD costs the cattle industry $1 billion
annually from death, reduced feed efficiency and treatment costs.1
iNFOrCE™ 3 is the first and only respiratory vaccine to be granted the “prevention of disease” indication, the highest label claim available for Brsv protection.
Respiratory disease remains the most economically devastating
condition in the beef industry2
• Approximately 75% of feedlot illnesses3,4,5
• 50% of feedlot deaths3,4,5
The second-most significant disease in dairy operations.6
• 22% of unweaned heifer deaths6 • 46% of weaned heifer deaths6
Brsv iBr
iNFOrCE 3 = NO DEATHs
All INFORCE 3 vaccinates survived
severe BRSV challenges, while almost
all unvaccinated controls died.10,11
20%
40%
60%
80%
100%
3- to 9-day-old calves*
(P 0.0001)
6- to 8-week-old calves*
(P 0.0001)
0%
–< –<
% M
orta
lity
100%90%
0% 0%
INFORCE 3 Control
iNFOrCE 3 = LEss LUNG DAMAGE
Fewer lung lesions due to BRSV
infections mean INFORCE 3 vaccinates
should be expected to require reduced
labor and treatment costs, and
improved productivity.9,10
20%
40%
60%
3- to 9-day-old calves*
(P=0.0006)
6- to 8-week-old calves*
(P<0.0001)
0%
% L
ung
Dam
age
57.6%
13.5%
43.8%
5.8%
INFORCE 3 Control
INFORCE 3 Control
iNFOrCE 3 = LEss iBr DisEAsE
Fewer sick calves mean less treatment
cost, reduced labor requirements
and decreased chance of secondary
bacterial infection.12,13
20%
40%
60%
80%
100%
3- to 9-day-old calves*
(P 0.0001)
6- to 8-week-old calves*
(P 0.0001)
0%
< <
% M
orbid
ity
100%100%
5.6% 5%
iNFOrCE 3 = LEss pi3 virUs sHEDDiNG
Compared with unvaccinated controls,
INFORCE 3 vaccinates shed 99.9% less
PI3 virus after challenge.14
99.9%LEss virUs sHED
Developed specifically for intranasal use.
• Helps stimulate local immunity• Triggers a rapid innate immune response• Helps provide protection where viruses attack first• Helps prime the immune system for a strong
memory response to subsequent disease challenges
pi3
• Immunosuppressive• May predispose cattle
to bacterial pneumonia9
• Easily spread• Causes severe upper
respiratory infections• Possible latent
infection
sUpEriOr prOTECTiON riGHT FrOM THE sTArT.
1 Brodersen BA, Bovine respiratory syncytial virus. Vet Clin Food Anim 2010;26:323-333.2 NAHMS Beef Cow/Calf Health & Productivity Audit; Part III: Beef Cow/Calf Health Management, January 2008. Available at: http://www.aphis.usda. Accessed July 2010.3 Edwards AJ. Respiratory diseases of feedlot cattle in the USA. Bovine Practitioner 1996;30:5-7.4 Galyean ML, Perino LJ, Duff CG. Interaction of cattle health/immunity and nutrition. J Anim Sci 1999;77:1120-1134.5 Loneragan DH, Dargatz DA, Morley PS, et al. Trends in mortality rates among cattle in U.S. feedlots. J Amer Vet Med Assoc 2001;219:1122-1127.6 NAHMS Dairy 2007 Part I: Reference of Dairy Cattle Health and Management Practices in the United States, October 2007. Available at: http://www.aphis.usda. Accessed July 2010.7 Steven T, Grubbs ST, Kania SA, Potgieter LND. Prevalence of ovine and bovine respiratory syncytial virus infections in cattle determined with a synthetic peptide-based immunoassay. J Vet Diagn Invest 2001;13:128–132. 8 Valarcher JF, Geraldine Taylor G. Bovine respiratory syncytial virus infection Vet Res 2007;38:153-180. 9 Ellis JA. Bovine parainfluenza-3 virus, Vet Clin Food Anim, 2010 (In press).10 Data on file, Study Report No. 3131R-60-08-557, Pfizer Inc.11 Data on file, Study Report No. 3131R-60-09-669, Pfizer Inc.12 Data on file, Study Report No. 3131R-60-08-580, Pfizer Inc. 13 Data on file, Study Report No. 3131R-60-09-720, Pfizer Inc. 14 Data on file, Study Report No. 3131R-60-08-568, Pfizer Inc.15 Data on file, Study Report No. 3437R-60-09-716, Pfizer Inc.16 Data on file, Study Report No. 3131R-60-09-671, Pfizer Inc.17 Data on file, Study Report No. 3131W-60-09-672, Pfizer Inc.
All brands are the property of Pfizer Inc., its affiliates and/or its licensors. ©2010 Pfizer Inc. All rights reserved. INF10006
Get your cattle off to a stronger, healthier start with iNFOrCE 3. To learn more, contact
your pfizer Animal Health representative, call 800-733-5500 or visit www.pfizerah.com.
Team up with your veterinarian to develop a complete vaccination protocol, starting with iNFOrCE™ 3.• INFORCE 3 helps give cattle a stronger start for greater productivity• Early protection can help reduce susceptibility to secondary bacterial infections• For dairy herds, use INFORCE 3 in baby calves, on arrival, at weaning,
before moving to group pens, or with cows and heifers prefreshening• INFORCE 3 is perfect for use in calves in beef herds at branding, preconditioning,
weaning, pre-shipment or on arrival in stocker or feedlots
A strong foundation for a complete vaccination protocol.
iNFOrCE 3 is available in four convenient dose sizes.
safe for use in all types, ages and classes of cattle.
The safety of iNFOrCE™ 3 was demonstrated in three separate studies.
1. Field safety study15:
The safety of INFORCE 3 was evaluated in a cattle safety study, which was one of the largest
ever conducted by Pfizer Animal Health. INFORCE 3 was administered intranasally to:
• 0- to 8-day-old calves • Pregnant cows in all three trimesters • Weaned calves • Total of 1,873 animals • High-stress stocker cattle • Three geographic locations
rEsULTs — iNFOrCE 3: sAFE iN ALL TYpEs, AGEs AND CLAssEs OF CATTLE
2. intensive safety study in young calves16:
INFORCE 3 and a commercial 5-way intranasal vaccine were both administered intranasally:
• A 10X concentrated dose to 3- to 10-day-old colostrum-deprived calves. • A dose of a commercial vaccine was administered parenterally to all animals 14 days
post-intranasal dose.
rEsULTs — iNFOrCE 3: sAFE iN YOUNG CALvEs
3. High-risk stocker study17:
INFORCE 3 and a commercial 5-way intranasal vaccine were both administered intranasally to:
• High-risk stocker calves on arrival at a feedlot
• A dose of a commercial vaccine was administered parenterally to all calves 14 days
post-intranasal dose
rEsULTs — iNFOrCE 3: sAFE iN HiGH-risK sTOCKEr CATTLE
sUpEriOr prOTECTiON riGHT FrOM THE sTArT.
1 Brodersen BA, Bovine respiratory syncytial virus. Vet Clin Food Anim 2010;26:323-333.2 NAHMS Beef Cow/Calf Health & Productivity Audit; Part III: Beef Cow/Calf Health Management, January 2008. Available at: http://www.aphis.usda. Accessed July 2010.3 Edwards AJ. Respiratory diseases of feedlot cattle in the USA. Bovine Practitioner 1996;30:5-7.4 Galyean ML, Perino LJ, Duff CG. Interaction of cattle health/immunity and nutrition. J Anim Sci 1999;77:1120-1134.5 Loneragan DH, Dargatz DA, Morley PS, et al. Trends in mortality rates among cattle in U.S. feedlots. J Amer Vet Med Assoc 2001;219:1122-1127.6 NAHMS Dairy 2007 Part I: Reference of Dairy Cattle Health and Management Practices in the United States, October 2007. Available at: http://www.aphis.usda. Accessed July 2010.7 Steven T, Grubbs ST, Kania SA, Potgieter LND. Prevalence of ovine and bovine respiratory syncytial virus infections in cattle determined with a synthetic peptide-based immunoassay. J Vet Diagn Invest 2001;13:128–132. 8 Valarcher JF, Geraldine Taylor G. Bovine respiratory syncytial virus infection Vet Res 2007;38:153-180. 9 Ellis JA. Bovine parainfluenza-3 virus, Vet Clin Food Anim, 2010 (In press).10 Data on file, Study Report No. 3131R-60-08-557, Pfizer Inc.11 Data on file, Study Report No. 3131R-60-09-669, Pfizer Inc.12 Data on file, Study Report No. 3131R-60-08-580, Pfizer Inc. 13 Data on file, Study Report No. 3131R-60-09-720, Pfizer Inc. 14 Data on file, Study Report No. 3131R-60-08-568, Pfizer Inc.15 Data on file, Study Report No. 3437R-60-09-716, Pfizer Inc.16 Data on file, Study Report No. 3131R-60-09-671, Pfizer Inc.17 Data on file, Study Report No. 3131W-60-09-672, Pfizer Inc.
All brands are the property of Pfizer Inc., its affiliates and/or its licensors. ©2010 Pfizer Inc. All rights reserved. INF10006
Get your cattle off to a stronger, healthier start with iNFOrCE 3. To learn more, contact
your pfizer Animal Health representative, call 800-733-5500 or visit www.pfizerah.com.
Team up with your veterinarian to develop a complete vaccination protocol, starting with iNFOrCE™ 3.• INFORCE 3 helps give cattle a stronger start for greater productivity• Early protection can help reduce susceptibility to secondary bacterial infections• For dairy herds, use INFORCE 3 in baby calves, on arrival, at weaning,
before moving to group pens, or with cows and heifers prefreshening• INFORCE 3 is perfect for use in calves in beef herds at branding, preconditioning,
weaning, pre-shipment or on arrival in stocker or feedlots
A strong foundation for a complete vaccination protocol.
iNFOrCE 3 is available in four convenient dose sizes.
safe for use in all types, ages and classes of cattle.
The safety of iNFOrCE™ 3 was demonstrated in three separate studies.
1. Field safety study15:
The safety of INFORCE 3 was evaluated in a cattle safety study, which was one of the largest
ever conducted by Pfizer Animal Health. INFORCE 3 was administered intranasally to:
• 0- to 8-day-old calves • Pregnant cows in all three trimesters • Weaned calves • Total of 1,873 animals • High-stress stocker cattle • Three geographic locations
rEsULTs — iNFOrCE 3: sAFE iN ALL TYpEs, AGEs AND CLAssEs OF CATTLE
2. intensive safety study in young calves16:
INFORCE 3 and a commercial 5-way intranasal vaccine were both administered intranasally:
• A 10X concentrated dose to 3- to 10-day-old colostrum-deprived calves. • A dose of a commercial vaccine was administered parenterally to all animals 14 days
post-intranasal dose.
rEsULTs — iNFOrCE 3: sAFE iN YOUNG CALvEs
3. High-risk stocker study17:
INFORCE 3 and a commercial 5-way intranasal vaccine were both administered intranasally to:
• High-risk stocker calves on arrival at a feedlot
• A dose of a commercial vaccine was administered parenterally to all calves 14 days
post-intranasal dose
rEsULTs — iNFOrCE 3: sAFE iN HiGH-risK sTOCKEr CATTLE